Researchers are making real progress on IPF (a lung scarring disease), with an AI finding a 7-drug combo that kept lung capacity nearly normal — and the global research community keeps growing.
FVC = how much air your lungs can push out. Higher % = healthier lungs. A typical IPF patient starts around 50–60%.
This is a computer model result — not a prescription. Always talk to your doctor before changing anything.
This week, the IPF research database grew to nearly 8,000 studies, with researchers all around the world — including large teams in Russia and China — working hard to understand why lungs develop scarring (hardening of tissue that makes breathing harder) and how to stop it. Most new papers this week came from other medical fields, which is actually helpful — discoveries about heart and liver disease often lead to breakthroughs in lung conditions too.
The AI system tested thousands of drug combinations and found one that kept lung capacity (FVC — a measure of how much air your lungs can hold) at 98.3%. That is almost completely normal. This combo used 7 drugs targeting different parts of the scarring process. This is still computer modeling, not a treatment yet, but it points scientists toward very promising directions to test in real clinical trials.
One question to ask your lung doctor at your next visit: "Are there any new combination therapy trials I might be eligible to join?"